Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223235 · ClinicalTrials.gov registry record · NA
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT01223235: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01223235 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01223235, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells. The purpose of this study is to test whether it is safe to treat the cancer with a vaccine and another drug called bevacizumab (also known as Avastin).
Interventions
- BIOLOGICAL bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-10 |
| Est. Completion | 2017-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01223235
The ClinicalTrials.gov registry entry for NCT01223235 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 is the first listed.
NCT01223235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01223235 about?
NCT01223235 is a clinical study titled "Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab". The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells. The purpose of this study is to test whether it is safe to treat the cancer with a vaccine and anot...
What is the current status of trial NCT01223235?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2010-10. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01223235?
The interventions under investigation include: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01223235?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.